Literature DB >> 17633921

[Expresion of E-cadherin and catenins in urothelial carcinomas].

P San Miguel Fraile1, C Gómez de María, L Donis Quintairos, A Carrera Vazquez, P Iglesias Martínez, M J Barreiro Barbosa.   

Abstract

OBJECTIVE: We examined the presence of E-cadherin and alpha, beta and gamma catenins detected by immunohistochemistry and correlated with the classic variables: grade, stage and recurrence. MATERIAL AND
METHOD: The authors evaluated 37 transitional cell carcinomas. Biopsy specimens included no recurrent transitional cell carcinoma (n=19) and recurrent transitional cell carcinoma (n=18). Association of E-cadherin and alpha, beta and gamma catenins immunoreactivity with tumor grade, clinical stage and tumor recurrence was examined.
RESULTS: E-cadherin and gamma catenin expression were related to the clinical stage of the disease, alpha and beta catenins were not correlated with grade, stage and recurrence of disease.
CONCLUSIONS: Decreased E cadherin and gamma catenin expression were associated with advanced stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17633921     DOI: 10.1016/s0210-4806(07)73649-5

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  2 in total

1.  WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Authors:  Wolfgang Otto; Johannes Breyer; Sonja Herdegen; Fabian Eder; Simone Bertz; Matthias May; Roman Mayr; Eva M Lausenmeyer; Stefan Denzinger; Bas W G van Rhijn; Maximilian Burger; Arndt Hartmann
Journal:  Int Urol Nephrol       Date:  2016-12-29       Impact factor: 2.370

Review 2.  Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis.

Authors:  Jacqueline M Benjamin; W James Nelson
Journal:  Semin Cancer Biol       Date:  2007-09-04       Impact factor: 15.707

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.